False claims act prosecution did not deter off-label drug use in the case of Neurontin

Health Affairs

Volumn 30, Issue 12, 2011, Pages 2318-2327

  Kesselheim, Aaron S ^a   Darby, Devan ^b   Studdert, David M ^b   Glynn, Robert ^a   Levin, Raisa ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GABAPENTIN;

ARTICLE; BILLING AND CLAIMS; DRUG INDUSTRY; DRUG MARKETING; DRUG TARGETING; EPILEPSY; FINANCIAL MANAGEMENT; FRAUD; HEALTH PROMOTION; HUMAN; ILLEGITIMACY; LAW ENFORCEMENT; MENTAL DISEASE; NEUROPATHIC PAIN; OFF LABEL DRUG USE; POSTHERPETIC NEURALGIA; PRESCRIPTION; PUNISHMENT; UNITED STATES;

AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INDUSTRY; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIABILITY, LEGAL; MARKETING; OFF-LABEL USE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84855682750     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2011.0370     Document Type: Article

References (34)

1. Department of Justice [Internet]. Washington (DC): Department of Justice. Press release, Warner-Lambert to pay $430 million to resolve criminal and civil health care liability relating to off-label promotion; 2004 May 13 [cited 2011 Oct 20]. Available from: http://www.justice.gov/opa/pr/2004/May/04_civ_322.htm
2. Mello MM, Studdert DM, Brennan TA. Shifting terrain in the regulation of off-label promotion of pharmaceuticals. N Engl J Med. 2009;360(15):1557-66.
3. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA. Characteristics and impact of drug detailing for gabapentin. PLoS Med. 2007;4(4):e134.
4. Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006;145(4): 284-93.
5. Landefeld CS, Steinman MA. The Neurontin legacy-marketing through misinformation and manipulation. N Engl J Med. 2009;360(2):103-6.
6. Pfizer. Ten questions: an open dialogue [Internet]. New York (NY): Pfizer; 2004 Dec 31 [cited 2011 Nov 10]. (2004 Annual Review). Available from: http://www.pfizer.com/investors/financial_reports/financial_reports_annualreview_2004.jsp
7. Kesselheim AS, Avorn J. The role of litigation in defining drug risks. JAMA. 2007;297(3):308-11.
8. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med. 2011;8(4):e1000431.
9. Taxpayers against Fraud. The 1986 False Claims Act Amendments: a retrospective look at twenty years of effective fraud fighting in America [Internet]. Washington (DC): TAF; [cited 2011 Oct 20]. Available from: http://www.taf.org/retrospective.pdf
10. Kesselheim AS, Studdert DM. Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005. Ann Intern Med. 2008;149(5): 342-9.
11. Iglehart JK. The ACA's new weapons against health care fraud. N Engl J Med. 2009;363(4):304-6.
12. Iglehart JK. Finding money for health care reform-rooting out waste, fraud, and abuse. N Engl J Med. 2009;361(3):230.
13. Becker D, Kessler D, McClellan M. Detecting Medicare abuse. J Health Econ. 2005;24:189-210.
14. United States Courts, Public Access to Court Electronic Records [home page on the Internet]. San Antonio (TX): PACER; [cited 2011 Oct 21]. Available from: http://www.pacer.gov/
15. Department of Justice. Justice news [home page on the Internet]. Washington (DC): Department of Justice; [cited 2011 Oct 21]. Available from: http://www.justice.gov/opa/pr/2010/November/index.html
16. Pfizer. Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934: for the quarterly period ended October 1, 2000 [Internet]. Washington (DC): Securities and Exchange Commission; [cited 2011 Nov 9]. Available from: http://www.sec.gov/Archives/edgar/data/78003/000007800300000049/0000078003-00-000049-0001.htm
17. To access the Appendix, click on the Appendix link in the box to the right of the article online
18. Mack A. Examination of the evidence for off-label use of gabapentin. J Manag Care Pharm. 2003;9(6): 559-68.
19. Armstrong D, Mathews AW. Pfizer case signals tougher action on offlabel drug use. Wall Street Journal. 2004 May 14.
20. Fullerton CA, Busch AB, Frank RG. The rise and fall of gabapentin for bipolar disorder: a case study on offlabel pharmaceutical diffusion. Med Care. 2010;48(4):372-79.
21. Manchanda P, Honka E. The effects and role of direct-to-physician marketing in the pharmaceutical industry: an integrative review. Yale J Health Policy Law Ethics. 2005; 5(2):785-822.
22. Patorno E, Bohn RL, Wahl PM, Avorn J, Patrick AR, Liu J, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14): 1401-9.
23. Kesselheim AS, Studdert DM, Mello MM. Experiences of whistleblowers in major fraud litigation against pharmaceutical companies. N Engl J Med. 2010;362:1832-9.
24. Sen. Grassley: over 1,000 healthcare fraud cases await government action. Becker's Hospital Review [serial on the Internet]. 2009 Oct 12 [cited 2011 Oct 24]. Available from: http://www.hospitalreviewmagazine.com/news-and-analysis/legal-and-regulatory/sen-grassleyover-1000-healthcare-fraud-casesawait-government-action.html
25. Qureshi ZP, Liu Y, Sartor O, Chu YH, Bennett CL. Enforcement actions involving Medicaid fraud and abuse, 1996-2009. Arch Intern Med. 2011; 171(8):785-7.
26. Meyer JA. Fighting Medicare fraud: more bang for the federal buck. Washington (DC): Taxpayers against Fraud; 2006.
27. Orsini-Meinhard K. Cell Therapeutics to pay $10.5 million to settle feds' suit. Seattle Times. 2007 Apr 18.
28. Kravitz RL, Epstein RM, Feldman MD, Franz CE, Azari R, Wilkes MS, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995-2002.
29. Backonja M, Beydoun A, Edwards KR, Schwartz SL, Fonseca V, Hes M, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998; 280(21):1831-6.
30. Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003;60(11):1524-34.
31. Garber A, Goldman DP, Jena AB. The promise of health care cost containment. Health Aff (Millwood). 2007;26(6):1545-7.
32. Davies SL, Jost TS. Managed care: placebo or wonder drug for fraud and abuse. Ga L Rev. 1997;31: 373-417.
33. Government Accountability Office. Health insurance: vulnerable payers lose billions to fraud and abuse. Washington (DC): GAO; 1992. (Pub. No. GAO/HRD-92-69).
34. Sparrow MK. License to steal: how fraud bleeds America's health care system. Boulder (CO): Westview Press; 2000.